• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Does the Type of Dietary Fat Affect Mortality and Heart Disease in Individuals with Type 2 Diabetes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Cardiovascular disease is the leading cause of death in adults with diabetes
  • Current guidelines recommend that patients with diabetes limit their intake of saturated fatty acids, trans fats, and cholesterol, and consume more omega-3s
    • Recommendations based on general population with limited data from individuals with type 2 diabetes
  • Jiao et al. (BMJ, 2019) sought to determine the association between dietary fatty acids, CVD mortality, and total mortality among patients with type 2 diabetes

METHODS:

  • Prospective, longitudinal cohort study
  • Participants: Patients with type 2 diabetes
    • Females: Nurses’ Health Study (1980-2014)
    • Males: Health Professionals Follow-Up Study (1986-2014)
  • Exposures
    • Dietary fat intake assessed using validated food frequency questionnaires
    • Updated every 2 to 4 years
  • Primary outcomes
    • Total mortality
    • CVD mortality

RESULTS:

  • 11,264 participants included in the 2 cohorts
  • Mortality risk was calculated using hazard ratio (HRs) across quarters of PUFA intake (multivariate analysis model)
    • HR ratios for mortality trended down with increasing polyunsaturated fatty acids (PUFA) intake for both CVD mortality (P for trend=0.03) and total mortality (P for trend<0.001)
  • Inverse associations with total mortality were also observed for intakes of total PUFAs, marine n-3 PUFAs, and linoleic acid
  • Monounsaturated fatty acids of animal, but not plant, origin associated with a higher total mortality
  • Theoretical models: Substituting PUFAs for other fats (same calories) demonstrated that replacing 2% of energy from saturated fatty acids with total PUFAs or linoleic acid was associated with lower CVD mortality
    • Total PUFAs: 13% lower CVD mortality (HR 0.87, 95% CI, 0.77 to 0.99)
    • Linoleic acid: 15% lower CVD mortality (HR 0.85, 95% CI, 0.73 to 0.99)
  • A 2% replacement of energy from saturated fatty acids with total PUFAs was associated with lower total mortality
    • Total PUFAs: 12% lower total mortality (HR 0.88, 95% CI, 0.83 to 0.94)

CONCLUSION:

  • Authors conclude that PUFAs, primarily linoleic acid and marine n-3 PUFAs, are preferable to saturated fats and carbohydrates for those individuals with type 2 diabetes

Our results suggest that dietary PUFAs, in replacement of saturated fatty acids or carbohydrates, may facilitate long term survival among adults with type 2 diabetes

Learn More – Primary Sources:

Dietary fats and mortality among patients with type 2 diabetes: analysis in two population based cohort studies

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Does the Mediterranean Diet Decrease Risk of Breast Cancer?
Does a Mediterranean Diet with Extra Olive Oil Decrease Risk of Gestational Diabetes Mellitus?
Does Eating a Mediterranean Diet Reduce Risk of Stroke in Both Men and Women?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site